Alvotech (ALVO) Depreciation & Amortization (CF) (2021 - 2026)
Alvotech (ALVO) posted Depreciation & Amortization (CF) of $10.3 million for Q1 2026, little changed on a QoQ basis from $10.3 million in Q3 2025, and up 24.56% year-over-year from $8.3 million in Q1 2025.
Alvotech (ALVO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Alvotech's Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $10.3 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 24.56% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (down 46.92% YoY) and the FY2023 annual result came in at $24.2 million, up 18.62% from the prior year.
- Depreciation & Amortization (CF) was $10.3 million for Q1 2026 at Alvotech, roughly flat from $10.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $31.3 million in Q4 2024 and bottomed at $4.7 million in Q1 2022.
- A 5-year average of $8.9 million and a median of $7.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) increased 3.2% — and 2024, when it jumped 365.44%.
- Alvotech's Depreciation & Amortization (CF) stood at $5.3 million in 2022, then climbed by 26.29% to $6.7 million in 2023, then soared by 365.44% to $31.3 million in 2024, then sank by 67.15% to $10.3 million in 2025, then rose by 0.05% to $10.3 million in 2026.
- Business Quant data shows ALVO's Depreciation & Amortization (CF) at $10.3 million in Q1 2026, $10.3 million in Q3 2025, and $8.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 10.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.29 Mn |
| Mar 31, 2026 | 10.29 Mn |
| Sep 30, 2025 | 10.28 Mn |
| Sep 30, 2025 | 10.28 Mn |
| Jun 30, 2025 | 8.90 Mn |
| Jun 30, 2025 | 8.90 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Dec 31, 2024 | 31.30 Mn |
| Dec 31, 2024 | 31.30 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Jun 30, 2024 | 7.56 Mn |
| Jun 30, 2024 | 7.56 Mn |
| Mar 31, 2024 | 7.19 Mn |
| Mar 31, 2024 | 7.19 Mn |
| Dec 31, 2023 | 6.73 Mn |
| Dec 31, 2023 | 6.73 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Jun 30, 2023 | 6.09 Mn |